-+ 0.00%
-+ 0.00%
-+ 0.00%
Adagene says China NMPA clears IND for ADG138 HER2xCD3 bispecific T-cell engager
Share
Listen to the news
Adagene says China NMPA clears IND for ADG138 HER2xCD3 bispecific T-cell engager
  • China’s NMPA cleared Adagene’s IND for ADG138, a double-masked HER2xCD3 bispecific T-cell engager for advanced solid tumors.
  • First-in-human Phase 1 trial in China is scheduled to start in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220800PRIMZONEFULLFEED9830693) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending